Julissa Clay

How does psoriasis prevalence differ across Europe, what percentage of men and women are affected, and how do healthcare systems differ in their approaches?

Hello, I’m Prakob Panmanee, though you might know me better as Mr. Hotsia. For the past 30 years, my life has been an open road. I traded a stable career as a government computer scientist for a backpack and a camera, with a mission to explore every corner of Thailand, Laos, Cambodia, Vietnam, and Myanmar. This journey wasn’t just about seeing new places; it was about understanding different ways of life. I’ve shared meals with farmers in remote villages, learned from artisans in bustling markets, and listened to stories that you’ll never find in a travel guide.

My travels gave me a profound appreciation for the connection between lifestyle, environment, and health. In many places I visited, healthcare isn’t about complex systems or expensive drugs, but about community support, traditional knowledge, and a deep, intuitive understanding of nature. This perspective became incredibly valuable when I later ventured into digital marketing, promoting high-quality health books and products to a Western audience. It allowed me to bridge the gap between ancient wisdom and modern science.

It’s with this unique lens—that of a traveler, an observer of cultures, and a student of both traditional and modern health—that I want to explore a condition like psoriasis within the context of Europe. It’s a place with some of the most advanced healthcare systems in the world, yet the story of psoriasis there is complex and varies dramatically from one border to another. It’s a story of numbers, of gender, and of systems, and it’s a fascinating contrast to the world I’ve spent three decades immersing myself in.

🗺️ A Continent of Contrasts: Psoriasis Prevalence Across Europe

One of the first things you learn as a traveler is that a single continent can hold a world of differences. The food, the language, the customs—they can change entirely in the space of a hundred kilometers. The same, it turns out, is true for psoriasis. There isn’t one “European” prevalence rate; there’s a patchwork quilt of statistics that vary significantly by country.

Generally, psoriasis is much more common in Western countries and among people of European descent. The numbers can be quite surprising. According to the Global Psoriasis Atlas, adult prevalence in Europe can range from as low as 0.11% in Switzerland to as high as 2.36% in Norway. Other studies have reported even higher figures in some Western European nations, with one source citing a prevalence of 4.6% in Norway and 4.42% in France. This stark variation highlights the complex interplay of genetics, environment, and lifestyle factors in triggering the condition. It’s fascinating to see Western Europe as a hotspot, while regions like Southeast Asia have some of the lowest incidence rates in the world. It makes you wonder what variables are at play—is it the diet, the climate, the genetic heritage, or something else entirely?

This geographical lottery means that your chances of having psoriasis can depend heavily on where you are born and live. The closer you get to the clear, cold climates of the north, the more common the condition seems to become.

🚻 A Shared Burden: Psoriasis in Men and Women

In my travels, I’ve seen how life’s burdens are often distributed differently between men and women, shaped by culture and tradition. When it comes to psoriasis, however, biology seems to be more of an equal-opportunity distributor. Most studies conclude that the overall prevalence of psoriasis is quite similar between men and women, hovering around a global average of 4%.

However, digging a little deeper reveals some interesting nuances. While the total number of people affected might be balanced, the way men and women experience the disease can differ. For example:

• Location of Lesions: Some studies suggest nail psoriasis is slightly more common in men, whereas a specific type called palmoplantar pustulosis is much more predominant in women. Genital psoriasis is also reported more frequently by men.
• Incidence Rates: At least one major Italian study found a slightly higher incidence (rate of new cases) in females (3.80 per 1,000 person-years) compared to males (2.96 per 1,000 person-years).
• Quality of Life: This is where a significant gap appears. Studies consistently show that women report a lower quality of life and feel more affected by their psoriasis than men, especially at the beginning of treatment. This highlights the different psychosocial impacts the condition can have, likely influenced by societal pressures and cultural factors.

So, while the chances of getting psoriasis may be roughly equal, the day-to-day experience of living with it is not always the same. It’s a reminder that health is not just about physical symptoms, but about the entire emotional and social context of a person’s life.

🏥 Navigating the System: Diverse Healthcare Approaches

This is where the differences across Europe become most apparent. From my perspective as someone who has witnessed healthcare in its most basic forms, the complex, highly structured systems in Europe are a world away. Yet, even within Europe, there is no single, unified approach to psoriasis care. Access to treatment, especially advanced therapies, can be a postcode lottery.

The foundation of treatment is generally consistent across the continent, following a stepwise approach defined by European-level guidelines.

1. Topical Treatments: For mild cases, care begins with creams and ointments, such as corticosteroids and vitamin D derivatives. This is the universal first step, from a village in Laos to a clinic in Berlin.
2. Phototherapy: For more widespread psoriasis, controlled UV light therapy is a common second-line treatment.
3. Systemic & Biologic Therapies: For moderate-to-severe disease, the journey moves to systemic drugs that work throughout the body. This is where the paths diverge significantly.

The primary difference lies in accessing the most advanced treatments: biologics. These revolutionary drugs have transformed care for severe psoriasis, offering the possibility of clear skin where older treatments failed. However, their high cost means that access is not uniform.

Different countries have different rules and hurdles:

• Reimbursement Criteria: Many national health systems require patients to fail on at least two older, “conventional” systemic drugs (like methotrexate or cyclosporine) before they can be approved for a biologic. This rule exists in countries like France and is common across Europe.
• Economic Barriers: Access is often tied to a country’s GDP. In some Central and Eastern European nations, the number of patients receiving biologics is drastically lower than in their wealthier Western European counterparts, a difference that can be as much as 14-fold. Restrictive criteria and budget limitations create significant barriers to care.
• Specialist Access: In many systems, care is managed by office-based dermatologists, with general practitioners playing a key role in initial diagnosis and referrals. However, a lack of training among primary care providers can lead to delayed diagnosis and undertreatment.

This creates a system where, despite having continent-wide medical guidelines, the actual care a patient receives can depend heavily on their nationality and their country’s economic health.

🌏 A Traveler’s Final Word: The Human Element in a World of Systems

After 30 years on the road, if there’s one thing I’ve learned, it’s that health is deeply personal. It’s a story told not just in statistics and guidelines, but in the daily lives of individuals. Looking at psoriasis in Europe is a powerful lesson in how systems, economies, and geography can shape that personal story.

The continent has achieved incredible medical advancements—biologics that can clear skin in ways that were once unimaginable. Yet, access to these breakthroughs is not universal. The journey of a person with psoriasis can be vastly different depending on whether they live in Oslo or Bucharest, a reality that feels dissonant in a place as interconnected as modern Europe.

It reminds me that no matter how sophisticated our systems become, we must never lose sight of the individual. The goal should always be to ensure that the best possible care is available to everyone, regardless of their gender, their location, or their country’s budget. It’s about combining the power of scientific innovation with the compassion and equity that I’ve been so fortunate to witness in the simplest of human interactions in villages all across Southeast Asia.

❓ Frequently Asked Questions (FAQ)

1. Is there a “psoriasis belt” in Europe?

While not an official term, the data strongly suggests a pattern where prevalence is highest in Western and Northern European countries, particularly Nordic nations like Norway and Denmark, and lower in Southern and Eastern Europe.

2. Why is psoriasis more common in Europe than in a region like Southeast Asia?

The exact reasons are a complex mix of genetics and environment. People of European descent have a higher genetic predisposition. Environmental factors, which could include diet, levels of sun exposure (UV light is a treatment for psoriasis), and lifestyle, are also thought to play a significant role in why the incidence is much lower in regions like Southeast Asia.

3. Do men and women need different types of treatment?

Generally, the medical treatments (topicals, biologics) are the same for men and women. However, a gender-sensitive approach means clinicians should be aware that women may report a higher impact on their quality of life and may have different lesion locations, which could influence the overall management plan to better address their psychosocial needs.

4. What is the biggest barrier to getting good psoriasis care in Europe?

While issues like lack of awareness and training exist, the most significant barrier, especially for severe psoriasis, is inconsistent and unequal access to advanced biologic therapies due to their high cost and the different reimbursement policies set by each country’s national healthcare system.

5. Are European treatment guidelines the same in every country?

There are overarching European guidelines (like the EUROGUIDERM) that provide a scientific basis for treatment. However, each country or region (like the UK’s NICE or France’s SFD) develops its own specific guidelines that adapt these recommendations to their national healthcare system, particularly regarding which drugs are funded and when.

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. Learn more